2,5-二异丙基-苯甲酸酰胺 | 683231-93-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 2,5-二异丙基-苯甲酸酰胺
• 英文名称: 2,5-diisopropyl-benzoic acid amide
• 英文别名: 2,5-Diisopropyl-benzoesaeure-amid；2,5-Di(propan-2-yl)benzamide
• CAS: 683231-93-8
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: FETKCINWGXWBHP-UHFFFAOYSA-N

物化性质

• 熔点：
  143.7-144.4 °C
• 沸点：
  284.4±29.0 °C(Predicted)
• 密度：
  0.985±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,5-二异丙基-苯甲酸酰胺 在 sodium hydroxide 作用下， 生成 2,5-Diisopropylbenzoic acid
  参考文献：
  名称：

  Polyisopropylbenzenes. V. Acetylation¹

  摘要：

  DOI：

  10.1021/ja01252a062
• 作为产物：
  描述：

  2,5-diisopropyl-benzonitrile 在 氢氧化钾 、 正丁醇 作用下， 生成 2,5-二异丙基-苯甲酸酰胺
  参考文献：
  名称：

  Polyisopropylbenzenes. V. Acetylation¹

  摘要：

  DOI：

  10.1021/ja01252a062

文献信息

• Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
  申请人：President and Fellows of Harvard College

  公开号：US11040976B2

  公开（公告）日：2021-06-22

  Provided herein are compounds of Formulae (RL), (I), (II), (III), (IV), and (V), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity). The compound are useful as substrate selective inhibitors of insulin-degrading enzyme (IDE).

  本文提供了式(RL)、(I)、(II)、(III)、(IV)和(V)化合物及其药学上可接受的盐、溶液剂、水合物、多晶型、共晶体、同分异构体、立体异构体、原药和同位素标记的衍生物。还提供了涉及本发明化合物的药物组合物、试剂盒和方法，用于治疗代谢紊乱（如糖尿病、高血糖、糖耐量受损、胰岛素抵抗、肥胖）。本发明化合物可作为胰岛素降解酶（IDE）的底物选择性抑制剂。
• Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US11066420B2

  公开（公告）日：2021-07-20

  Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.

  蛋白酪氨酸磷酸酶（PTPs）是新陈代谢和胰岛素信号传导的关键调节因子。作为胰岛素信号转导的负调控因子，低分子量蛋白酪氨酸磷酸酶（LMPTP）是胰岛素抵抗及相关疾病的靶标。本文描述了能够调节低分子量蛋白酪氨酸磷酸酶（LMPTP）活性水平的化合物和组合物，以及使用这些化合物和组合物的方法。
• SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF
  申请人：President and Fellows of Harvard College

  公开号：US20180194768A1

  公开（公告）日：2018-07-12

  Provided herein are compounds of Formulae (RL), (I), (II), (III), (IV), and (V), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity). The compound are useful as substrate selective inhibitors of insulin-degrading enzyme (IDE).
• SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF
  申请人：President and Fellows of Harvard College

  公开号：US20190016723A9

  公开（公告）日：2019-01-17

  Provided herein are compounds of Formulae (RL), (I), (II), (III), (IV), and (V), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity). The compound are useful as substrate selective inhibitors of insulin-degrading enzyme (IDE).
• INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US20200055875A1

  公开（公告）日：2020-02-20

  Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.